الفهرس Only 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
Role of vascular endothelial growth factor in prognosis and management of hepatocellular carcinoma. Association of VEGF overexpression with poor outcomes provides a rationale for anti - angiogenics use in the treatment of cancer. VEGF has become a leading therapeutic target for the treatment of cancer. Potentially therapeutic strategies to inhibit VEGF pathway include monoclonal antibodies directed against VEGF and tyrosine kinase inhibitors (TKIs). In conclusion, results suggest that plasma IGF - 1 may serve as a new tool for assessing liver reserve in patients with HCC and that baseline plasma assessment of both IGF - 1 and VEGF significantly improves prediction of OS and prognostic stratification of patients with HCC according to BCLC staging